Cabaletta Bio (NASDAQ: CABA) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Cabaletta released 2Q21 earnings that were essentially a non-event, as is often the case for a clinical-stage company. More important are updates on the progress of lead program DSG3-CAART, and we are encouraged by the DesCAARTes trial update that no dose limiting toxicities or clinically relevant adverse events have been observed to date, while we await key target engagement data that the company expects to provide 3 to 6 months after completion of dosing of each cohort. Management also expects to submit an IND for MuSK-CAART in myasthenia gravis, and hold a pre-IND meeting with FDA for their PLA2R-CAART program in membranous nephropathy in 2H21. We maintain our $22 PT, and reiterate our Buy rating.”
To request access to the full report, visit http://nnw.fm/SaZ9d
About Cabaletta Bio Inc.
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA(TM)) platform, in combination with Cabaletta’s proprietary technology, utilizes Chimeric AutoAntibody Receptor (“CAAR”) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The company’s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes(TM) Phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the DesCAARTes(TM) Phase 1 clinical trial, please see www.clinicaltrials.gov. The company’s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit the company’s website at www.cabalettabio.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
